/
Musculoskeletal
Osteoarthritis
109
Pipeline Programs↗
321
Active Trials↗
157
Companies Involved↗
Osteoarthritis is a highly competitive landscape with 109 programs across 157 companies. The most active players are Pacira Pharmaceuticals, Inc, Ageless Biotech, Inc., Akan Biosciences, LLC. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical71
Phase 19
Phase 214
Phase 315
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
78 of 85 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 85 classified programs, each share of the total. Modality classified for 95% of 109 pipeline programs.
Analysis
Trial Status
1,271
clinical trials
Completed715 · 56%
Recruiting155 · 12%
Unknown status126 · 10%
Not yet recruiting95 · 7%
Terminated70 · 6%
Active, not recruiting64 · 5%
Other46 · 4%
Clinical Trials
Trial Activity
1271 trials
Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance
Recruiting·—·Approved·NCT07759336·85 enrolled
Page 1 of 85
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)